 I. To determine progression-free survival PFS. II. To determine overall survival OS. III. To determine duration of tumor response. IV. To determine safety and tolerability of lenvatinib. V. To assess patient reported quality of life using EuroQol Five-Dimensional Five Level Scale Questionnaire EQ-5D-5L and Functional Assessment of Cancer Therapy-General FACT-G. 